Literature DB >> 21430656

The use of induced pluripotent stem cells in drug development.

H Inoue1, S Yamanaka.   

Abstract

Induced pluripotent stem cell (iPSC) technology is revolutionizing medical science, allowing the exploration of disease mechanisms and novel therapeutic molecular targets, and offering opportunities for drug discovery and proof-of-concept studies in drug development. This review focuses on the recent advancements in iPSC technology including disease modeling and control setting in its analytical paradigm. We describe how iPSC technology is integrated into existing paradigms of drug development and discuss the potential of iPSC technology in personalized medicine.

Mesh：

Year:  2011        PMID： 21430656     DOI： 10.1038/clpt.2011.38

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  90 in total

1.  Three-Dimensional Hyaluronic Acid Hydrogel-Based Models for In Vitro Human iPSC-Derived NPC Culture and Differentiation.

Authors:  Shaohua Wu; Ranjie Xu; Bin Duan; Peng Jiang
Journal:  J Mater Chem B       Date:  2017-04-19       Impact factor: 6.331

2.  Purging and isolating pluripotent cells, "sweet" dreams become true?

Authors:  Ignacio Sancho-Martinez; Emmanuel Nivet; Juan Carlos Izpisua Belmonte
Journal:  Cell Res       Date:  2011-10-25       Impact factor: 25.617

3.  Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement.

Authors:  Stephen T Bartlett; James F Markmann; Paul Johnson; Olle Korsgren; Bernhard J Hering; David Scharp; Thomas W H Kay; Jonathan Bromberg; Jon S Odorico; Gordon C Weir; Nancy Bridges; Raja Kandaswamy; Peter Stock; Peter Friend; Mitsukazu Gotoh; David K C Cooper; Chung-Gyu Park; Phillip OʼConnell; Cherie Stabler; Shinichi Matsumoto; Barbara Ludwig; Pratik Choudhary; Boris Kovatchev; Michael R Rickels; Megan Sykes; Kathryn Wood; Kristy Kraemer; Albert Hwa; Edward Stanley; Camillo Ricordi; Mark Zimmerman; Julia Greenstein; Eduard Montanya; Timo Otonkoski
Journal:  Transplantation       Date:  2016-02       Impact factor: 4.939

4.  Metabolome and metaboproteome remodeling in nuclear reprogramming.

Authors:  Clifford Dl Folmes; D Kent Arrell; Jelena Zlatkovic-Lindor; Almudena Martinez-Fernandez; Carmen Perez-Terzic; Timothy J Nelson; Andre Terzic
Journal:  Cell Cycle       Date:  2013-07-08       Impact factor: 4.534

Review 5.  Vascularized microfluidic organ-chips for drug screening, disease models and tissue engineering.

Authors:  Tatsuya Osaki; Vivek Sivathanu; Roger D Kamm
Journal:  Curr Opin Biotechnol       Date:  2018-04-12       Impact factor: 9.740

6.  Overexpression of cyclin dependent kinase inhibitor P27/Kip1 increases oligodendrocyte differentiation from induced pluripotent stem cells.

Authors:  Shinpei Tamaki; Yasuhito Tokumoto
Journal:  In Vitro Cell Dev Biol Anim       Date:  2014-04-25       Impact factor: 2.416

7.  Reengineering translational science: the time is right.

Authors:  Francis S Collins
Journal:  Sci Transl Med       Date:  2011-07-06       Impact factor: 17.956

Review 8.  Use of human pluripotent stem cells to study and treat retinopathies.

Authors:  Karim Ben M'Barek; Florian Regent; Christelle Monville
Journal:  World J Stem Cells       Date:  2015-04-26       Impact factor: 5.326

9.  Nuclear reprogramming with c-Myc potentiates glycolytic capacity of derived induced pluripotent stem cells.

Authors:  Clifford D L Folmes; Almudena Martinez-Fernandez; Randolph S Faustino; Satsuki Yamada; Carmen Perez-Terzic; Timothy J Nelson; Andre Terzic
Journal:  J Cardiovasc Transl Res       Date:  2012-12-18       Impact factor: 4.132

10.  Disease-corrected hepatocyte-like cells from familial hypercholesterolemia-induced pluripotent stem cells.

Authors:  Faranak Fattahi; Samira Asgari; Behshad Pournasr; Ali Seifinejad; Mehdi Totonchi; Adeleh Taei; Nasser Aghdami; Ghasem Hosseini Salekdeh; Hossein Baharvand
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.